Here are the top regulatory news stories this week: The FDA approved Amgen’s biosimilar to Roche’s cancer treatment Avastin (bevacizumab). Amgen’s biosimilar was approved under the brand name Mvasi (bevacizumab-awwb):  http://www.raps.org/Regulatory-Focus/News/2017/09/14/28467/FDA-Approves-First-Biosimilar-Cancer-Treatment/ FDA commissioner Scott Gottlieb announced Tuesday that the agency will release guidance to close a loophole that allows companies to avoid their obligation to[…]